Media Update, page-367

http://www.cepii.fr/PDF_PUB/pb/2016/pb2016-12.pdf

Hi there. A lot of what’s going to happen with aspiral is going to depend on China’s 13th FYP (2016-2020). Management has always guided us that demand for aspiral will be back ended. So this year and next 2020 will be key. I have no reason to disbelieve management although their timing can be a bit off. 
 
For me, the significant US$45m order over 3 years by iTest is really key for me. For an industry that moves slower than a snail’s pace, clinching an order with 3 years of commercial launch is very unusual. Only China which is driven by technology can move at that pace, not India, not USA, not even Singapore where I live. 

Some may  not like China with its dubious practices. Singaporeans have had our fair share of being snookered over there. Yet it’s a market place that has be engaged and managed, not ignored. The size is simply too large. Question is whether the Israelis are up to scratch. With their history, I believe they have a chance of succeeding. Singapore and Israel have similar traits in that we are small and live in a neighbourhood not always well liked. We know what we need to do to preserve our interests and that includes walking away from some deals, and knowing which battles to fight. So, I am confident I am in good hands. All IMO, of course.